Efficacy results in seasonal allergies

Mean change from baseline in total symptom severity complex (TSSC) scores in patients with SAR¹ 

_{†Based on main effects models for intent-to-treat population. Week 2 was designated as the primary endpoint. Endpoint = last post-baseline observation. ‡P < 0.01; §P < 0.001.  
Adapted from Noonan, et al.}  

The TSSC score includes: 

• Sneezing 

• Runny nose 

• Itchy nose 

• Itchy eyes 

• Watery eyes 

• Post-nasal drip 

Change from baseline to Week 2 in individual SAR symptoms   

REACTINE® provided symptom relief from watery eyes as well as relief of sneezing, runny nose, and itchy nose vs placebo¹ 

• Multicenter study included 403 patients with SAR, symptoms based on a 4-point scale (0=none to 3=severe) 

• Significant differences were observed for each individual symptom compromising the TSSC with the exception of nasal congestion at Week 2 

• Mean change from baseline (with the exception of nasal congestion) to Week 2 showed significantly greater improvement in patients treated with REACTINE® compared with patients treated with placebo (P≦0.01). 

Mean reduction from baseline to week 2 in SAR symptom scores¹ 

_{॥Based on main effects models on intent-to-treat population. ¶P < 0.001, **P < 0.01, ††P<0.05. 
Adapted from Noonan, et al.}